Abstract
PD-L1 expression is the most implemented biomarker in clinical practice for immunotherapy in NSCLC; however, not all patients benefit from this treatment and PD-L1 testing alone is not yet an adequate biomarker for patient selection. Consequently, new approach is necessary to identify effective biomarkers. The aim of the project is to characterize T cell receptor β chain (TCRβ) repertoire in a cohort of advanced NSCLC patients treated with anti-PD1.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
